UA-45667900-1

Wednesday, 8 November 2023

Glycine-NAC for longevity, but for Autism? and Ketogenic “Autistic” Fish


Fish taking a ketone ester

Lonesome fish

  

Baylor College of Medicine in the US have a patent on the combination of glycine and the anti-oxidant NAC to promote healthy aging, which they licensed to Nestle. You can easily make it yourself - just buy both separately. 

GlyNAC supplementation reverses mitochondrial dysfunction, oxidative stress and aging hallmarks to boost strength and promote health in aging humans

One of the intriguing questions from this trial is why so many improvements occur toward promoting health. We believe that this is due to the combined effort of three separate components – glycine, cysteine (from NAC) and glutathione, and not just due to glutathione itself. Glycine and cysteine are both very important for cellular health on their own, and GlyNAC provides both. 

We believe that the improvements in this trial and in our previous studies are the result of the combined effects of glycine and NAC and glutathione, and we refer to this combination as the "Power of 3" said Sekhar.

You need cysteine and glycine to make the body's key antioxidant, glutathione (GSH).  Older people and people with autism are likely to lack GSH.

If you add the precursors via supplementation, you will hopefully increase the production of GSH.



  

GlyNAC (Glycine and N-Acetylcysteine) Supplementation in Mice Increases Length of Life by Correcting Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Abnormalities in Mitophagy and Nutrient Sensing, and Genomic Damage

Determinants of length of life are not well understood, and therefore increasing lifespan is a challenge. Cardinal theories of aging suggest that oxidative stress (OxS) and mitochondrial dysfunction contribute to the aging process, but it is unclear if they could also impact lifespan. Glutathione (GSH), the most abundant intracellular antioxidant, protects cells from OxS and is necessary for maintaining mitochondrial health, but GSH levels decline with aging. Based on published human studies where we found that supplementing glycine and N-acetylcysteine (GlyNAC) improved/corrected GSH deficiency, OxS and mitochondrial dysfunction, we hypothesized that GlyNAC supplementation could increase longevity. We tested our hypothesis by evaluating the effect of supplementing GlyNAC vs. placebo in C57BL/6J mice on (a) length of life; and (b) age-associated GSH deficiency, OxS, mitochondrial dysfunction, abnormal mitophagy and nutrient-sensing, and genomic-damage in the heart, liver and kidneys. Results showed that mice receiving GlyNAC supplementation (1) lived 24% longer than control mice; (2) improved/corrected impaired GSH synthesis, GSH deficiency, OxS, mitochondrial dysfunction, abnormal mitophagy and nutrient-sensing, and genomic-damage. These studies provide proof-of-concept that GlyNAC supplementation can increase lifespan and improve multiple age-associated defects. GlyNAC could be a novel and simple nutritional supplement to improve lifespan and healthspan, and warrants additional investigation.

 

Glycine and N‐acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: Results of a pilot clinical trial


GlyNAC supplementation for 24‐weeks in OA was well tolerated and lowered OxS, corrected intracellular GSH deficiency and mitochondrial dysfunction, decreased inflammation, insulin‐resistance and endothelial dysfunction, and genomic‐damage, and improved strength, gait‐speed, cognition, and body composition. Supplementing GlyNAC in aging humans could be a simple and viable method to promote health and warrants additional investigation.

 


 

 

Multifarious Beneficial Effect of Nonessential Amino Acid, Glycine: A Review

Glycine is most important and simple, nonessential amino acid in humans, animals, and many mammals. Generally, glycine is synthesized from choline, serine, hydroxyproline, and threonine through interorgan metabolism in which kidneys and liver are the primarily involved. Generally in common feeding conditions, glycine is not sufficiently synthesized in humans, animals, and birds. Glycine acts as precursor for several key metabolites of low molecular weight such as creatine, glutathione, haem, purines, and porphyrins. Glycine is very effective in improving the health and supports the growth and well-being of humans and animals. There are overwhelming reports supporting the role of supplementary glycine in prevention of many diseases and disorders including cancer. Dietary supplementation of proper dose of glycine is effectual in treating metabolic disorders in patients with cardiovascular diseases, several inflammatory diseases, obesity, cancers, and diabetes. Glycine also has the property to enhance the quality of sleep and neurological functions. In this review we will focus on the metabolism of glycine in humans and animals and the recent findings and advances about the beneficial effects and protection of glycine in different disease states. 

As glycine is a very successful immunomodulator that suppresses the inflammation, its action on arthritis is investigated in vivo through PG-PS model of arthritis. PG-PS is a very crucial structural component of Gram-positive bacterial cell walls and it causes rheumatoid like arthritis in rats. In rats injected with PG-PS which suffer from infiltration of inflammatory cells, synovial hyperplasia, edema, and ankle swelling, these effects of PG-PS model of arthritis can be reduced by glycine supplementation [66].

 

Glycine has a wide spectrum of defending characteristics against different injuries and diseases. Similar to many other nutritionally nonessential amino acids, glycine plays a very crucial role in controlling epigenetics. Glycine has much important physiological function in humans and animals. Glycine is precursor for a variety of important metabolites such as glutathione, porphyrins, purines, haem, and creatine. Glycine acts as neurotransmitter in central nervous system and it has many roles such as antioxidant, anti-inflammatory, cryoprotective, and immunomodulatory in peripheral and nervous tissues. Oral supplementation of glycine with proper dose is very successful in decreasing several metabolic disorders in individuals with cardiovascular disease, various inflammatory diseases, cancers, diabetes, and obesity. More research investigations are needed to explore the role of glycine in diseases where proinflammatory cytokines, reperfusion or ischemia, and free radicals are involved. Mechanisms of glycine protection are to be completely explained and necessary precautions should be taken for safe intake and dose. Glycine holds an enormous potential in enhancing health, growth, and well-being of both humans and animals.

  

Ketogenic Fish – rebuilding social affinity 

Regular readers will have noted that some people with autism, but normal IQ, are deeply troubled by their lack of social affinity and seek out ways to improve it.

Perhaps we can learn something on that subject from Masato Yoshizawa, an evolutionary developmental biologist and neurobiologist at the University of Hawaii. Yes, that’s right, an evolutionary developmental biologist – they exist! Back in 2018 he published a paper called “The evolution of a series of behavioral traits is associated with autism-risk genes in cavefish”.

“Many people first doubted that the fish have an autism-like state; I also doubted it at first,” said Yoshizawa. But as he soon found out, even patterns of gene regulation resembled autistic patients.

His recent paper uses his cavefish to look at how the ketogenic diet affects behaviour. 

In the experiment, cavefish where fed the same ketogenic milk provided to human patients, albeit with a few modifications for fish consumption, and their behavior was monitored. As a comparison, a type of A. mexicanus fish that lives in rivers and not caves were also tested.


The surface fish do not display the same autism like behaviors as their cave dwelling relatives. In the presence of other surface fish, individuals will begin to follow each other and swim together, something rarely seen in cavefish, Yoshizawa said. The surface fish also do not do the repetitive behavior of swimming in circles.

 

Using these fish as a comparison, Yoshizawa and his students watched and waited. Amazingly, after a month of the ketogenic diet, the cavefish began to act like the more social surface fish. They would follow each other in groups and ceased going round in circles. There were some other behaviors, such as attention to a specific task and sleeping, that were unaffected, but overall the results were promising and according to Yoshizawa, suggest dopamine could be key to how the diet affects behavior.

 

According to Yoshizawa, there are two plausible ideas as to how the ketones produced by a ketogenic diet are acting on behavior. The first involves the mitochondria, which use either carbs or fat to produce energy in our cells, and the other involves epigenetics, which simple refers to any non-genetic influence which turns genes on and off.

 

Ketones are known to create detectable increases in gene expression in cells. Pulling apart exactly how things like, diet, environment, genes and neurotransmitters are linked is incredibly difficult but could reveal which pathways are best to target for autism treatments or could identify a specific ketone which works more efficiently than others.

 

 

Cavefish provide clues to the keto diet's effect on autism-like behavior 

 

Metabolic shift toward ketosis in asocial cavefish increases social-like affinity

 

Background

Social affinity and collective behavior are nearly ubiquitous in the animal kingdom, but many lineages feature evolutionarily asocial species. These solitary species may have evolved to conserve energy in food-sparse environments. However, the mechanism by which metabolic shifts regulate social affinity is not well investigated.

Results

In this study, we used the Mexican tetra (Astyanax mexicanus), which features riverine sighted surface (surface fish) and cave-dwelling populations (cavefish), to address the impact of metabolic shifts on asociality and other cave-associated behaviors in cavefish, including repetitive turning, sleeplessness, swimming longer distances, and enhanced foraging behavior. After 1 month of ketosis-inducing ketogenic diet feeding, asocial cavefish exhibited significantly higher social affinity, whereas social affinity regressed in cavefish fed the standard diet. The ketogenic diet also reduced repetitive turning and swimming in cavefish. No major behavioral shifts were found regarding sleeplessness and foraging behavior, suggesting that other evolved behaviors are not largely regulated by ketosis. We further examined the effects of the ketogenic diet via supplementation with exogenous ketone bodies, revealing that ketone bodies are pivotal molecules positively associated with social affinity.

Conclusions

Our study indicated that fish that evolved to be asocial remain capable of exhibiting social affinity under ketosis, possibly linking the seasonal food availability and sociality.

 

Are these behavioral and growth changes induced by ketosis? The KD contains high amounts of fat, sufficient levels of proteins, and a minimum amount of carbohydrates. This question motivated us to test the molecular basis of the effects of KD feeding by supplementing major ketosis metabolites, ketone bodies, to the standard diet.

 

In humans, KD feeding induces ketosis, in which the liver releases beta-hydroxybutyrate (BHB) and acetoacetate via beta-oxidation of fat [63].

 

Instead of supplying a massive amount of fat using the KD, BHB might be responsible for the majority of effects observed after KD feeding. With this idea, the ketone ester (D-b-hydroxybutyrate-R 1,3-Butanediol Monoester; delta-G® [64]) was provided as a supplement to both surface fish and cavefish for 5 weeks. The ketone ester (KE) was expected to undergo complete hydrolysis by the gut esterases, resulting in two BHB molecules (and acetoacetate) [64]. It does not contain any salt ions, unlike the sodium or potassium salt forms of BHB, nor does it has the racemic L-form, where only the D-form is considered to be biologically active [65]. Since we were unsure whether gut esterases were available in juvenile-adolescent fish at 3 months old, we used 6–7-month-old fish that have a mature gut system but are in the young adult stage. The results indicated that the KE supplementation significantly reduced the serum GKI (Additional file 2: Fig. S8), while promoting nearby interactions in cavefish (Fig. 7A, B). Swimming distance was slightly reduced in cavefish (Fig. 7C). Turning bias was not reduced by KE supplementation in cavefish (Fig. 7D). There was no detectable difference between CD and KE supplemental diets in sleep duration or VAB (Additional file 2: Fig. S9A and B, respectively).

  

We also tested the supplemental feeding of the BHB salt form (sodium salt form of racemic BHB: 50% L-form and 50% D-form). We used 11–12-month-old fish in this study since the younger fish seemed to suffer from the high-salt-containing diet. The 4-week feeding result was essentially the same as the KE-supplemented diet feeding: the BHB salt supplemental diet significantly reduced GKI in the serum of surface and cavefish (Additional file 2: Fig. S10), while promoting nearby interactions in cavefish but reduced the duration of nearby interactions in surface fish (Additional file 2: Fig. S11A, B). No major change in response to the BHB feeding was detected in swimming distance (Additional file 2: Fig. S11C), turning bias (Additional file 2: Fig. S11D), sleep (Additional file 2: Fig. S12A), and VAB (Additional file 2: Fig. S12B) in cavefish, while the BHB salt reduced growth (standard length and weight) in surface fish (Additional file 2: Fig. S12C, D). In contrast, cavefish did not show any detectable negative effects on growth under the BHB salt supplemental feeding (Additional file 2: Fig. S12C, D).

 

In summary, BHB (KE and BHB salt) treatment encompassed the effect of the KD treatment—promoting social interactions. BHB, particularly KE, had a no-detectable negative effect on growth. These facts suggest that ketone bodies can be responsible factors for the positive effects on social behaviors of KD feeding. BHB treatment also indicated that older-age cavefish (6–7 months or 11–12 months old) were still capable of responding to ketone bodies, not only younger age groups (3–4 months old).

 

You can treat an old-fish new tricks!

Indeed, some of our adult readers are treating themselves with ketone esters.

Both ketone esters and ketone salts were trialed in the fish. In humans ketone esters are the clear winner because they provide a much longer lasting effect.

There is no reason why they have to be so expensive, the bulk chemical is not expensive.

  

Conclusion

For longevity and, more importantly, healthy life expectancy it has long been clear that high doses of anti-oxidants are beneficial.

The question is how best to get this effect.

The most potent way is via intravenous infusion of something like ALA (alpha lipoic acid). In some countries intravenous ALA is a mainstream therapy for people with diabetes, not surprisingly thanks to the ALA some of these people also overcome their other health conditions, like heart disease, and increase their healthy lifespan.

Most people will not have this option and probably do not want intravenous therapy anyway.

Oral supplementation with NAC is cheap, effective and available.

Is adding glycine going to have any incremental effect?  Quite possibly it will. If you are lacking glycine, this will hold back your production of GSH (glutathione). Glycine itself might well provide a health benefit.

Dr Sekhar, over at Baylor College in Houston, refers to the “power of three” (NAC, glycine and glutathione/GSH). The immediate, short-lived, beneficial effect is directly from the anti-oxidant effect of NAC itself.

If, like me, you have chosen to take NAC you are experiencing the “power of two” (NAC and Glutathione/GSH).  Glycine is really cheap and so why not take the extra step and add it? You may increase Glutathione/GSH and glycine has its own direct antioxidant and anti-inflammatory properties.

When it comes to young people with autism who take NAC, is the benefit from the immediate antioxidant effect of NAC, or is it from the increase in GSH?  Here I think we know the answer.  The behavioral effect of NAC is quite short-lived and it matches the short half-life of NAC.  Is there a secondary effect from NAC releasing cysteine that gradually increases GSH (glutathione)? Quite possibly, but in autism you really do need to give NAC 3-4 times a day, so the direct effect of NAC itself looks to be key.

Is Glycine NAC going to be better than NAC for young people with autism? Glycine has its own interesting properties and glycine is cheap. It even can help some of those with sleep problems (3g one hour before bed time).

There are plenty of anecdotal reports on the internet of Aspies finding glycine supplementation helpful - some find it makes them more social.

There is a potential problem for bumetanide-responders. In these people if GABA is operating "in reverse", due to high intracellular chloride, the same may be true of glycine. You would then expect a negative reaction

GABA and glycine in the developing brain

GABA and glycine are major inhibitory neurotransmitters in the CNS and act on receptors coupled to chloride channels. During early developmental periods, both GABA and glycine depolarize membrane potentials due to the relatively high intracellular Cl concentration. Therefore, they can act as excitatory neurotransmitters. GABA and glycine are involved in spontaneous neural network activities in the immature CNS such as giant depolarizing potentials (GDPs) in neonatal hippocampal neurons, which are generated by the synchronous activity of GABAergic interneurons and glutamatergic principal neurons. GDPs and GDP-like activities in the developing brains are thought to be important for the activity-dependent functiogenesis through Ca 2+ and/or other intracellular signaling pathways activated by depolarization or stimulation of metabotropic receptors. However, if GABA and glycine do not shift from excitatory to inhibitory neurotransmitters at the birth and in maturation, it may result in neural disorders including autism spectrum disorders.

 

And those ketone esters (KE)?

Well they are really expensive, when packaged up for humans, but they should be helpful to a sub-group within autism.

Will ketone esters (KE) make our reader Stefan feel more social? Quite possibly, but they are likely too expensive to take every day. Glycine is cheap and worth a try for social affinity, based on the anecdotes from other Aspies.

Some readers are already big fans of ketone esters.  They do not need any further proof from those cavefish in Hawaii.











Monday, 30 October 2023

eIF3f-related neurodevelopmental disorder

 


Source: https://ojrd.biomedcentral.com/articles/10.1186/s13023-021-01744-1/figures/2


I recently received an email from a mother in New Zealand asking about what might help her adult son, recently diagnosed with an extremely rare type of “autism” called elF3f - related neurodevelopmental disorder.

This post is just based on a preliminary investigation, I think much more would be possible if a serious full-time review was made. This applies to all the other single gene autisms that are “untreatable”.

 

eIF3f (eukaryotic translation initiation factor 3 subunit f)

elF3f is one of the more complicated genes/proteins with multiple functions. In layman’s terms it is involved in making all the other proteins.

eIF3f is a subunit of the eIF3 complex, hence the “f” on the end. It is required for several steps in the initiation of protein synthesis.

We saw how elF4 plays a role in how Fragile X causes intellectual disability. eIF4 is another translation initiation factor that plays a key role in the initiation of protein synthesis.

The eIF4 complex and the eIF3 complex interact with each other to form the translation initiation complex. This complex is responsible for bringing together the mRNA, the ribosome, and the initiator tRNA, which allows protein synthesis to begin.  I did warn you it gets complicated!

eIF4 and eIF3 are both essential for the initiation of protein synthesis.

eIF3f is also involved in the regulation of cell growth and proliferation, making it a target gene in cancer therapy, where eIF3f can be overexpressed or under-expressed.

 

In spite of what the Simon’s Foundation’s Searchlight project


Simons Search - Partnering with families. Understanding genetic changes.

Driven by science. United by hope

In order to create scientific breakthroughs for rare genetic neurodevelopmental disorders, families and scientists must come together. Simons Searchlight‘s mission is to shed light on these disorders by collecting high-quality, standardized natural history data and building strong partnerships between researchers, industry and families. Families like yours are the key to making meaningful progress.

 

and others say that “at this point, there are no medicines designed to treat the syndrome”, there certainly are potential treatment strategies available.

The mother did question whether there are similarities with Rett syndrome.  You can apparently reduce expression of eIF3f using the common supplement EGCG (Epigallocatechin Gallate). EGCG has been found to benefit Rett syndrome.

I think what is likely required for eIF3f-related neurodevelopmental disorder is the exact opposite, which is to increase expression of eIF3f.

 

Sources of data:-

 

GeneCards - EIF3F Gene - Eukaryotic Translation Initiation Factor 3 Subunit F

https://www.genecards.org/cgi-bin/carddisp.pl?gene=EIF3F

RGD - EIF3F (eukaryotic translation initiation factor 3 subunit F) Homo sapiens

https://rgd.mcw.edu/rgdweb/report/gene/main.html?id=1314535

 

The above two sites do provide a great deal of information, but I think a lot is auto-generated and there are mistakes.

What we are looking for are safe substances that change expression of the gene eIF3f.

According to GeneCards there is only one substance - quercetin.

According to RGD there is a long list.  This did look very promising, but when I looked at the linked references I did not always find that the supporting data exists.  This is a problem with AI (artificial intelligence), it can make things up.

Sometimes you have to go back to the basic science.

There is evidence that activating the PI3K/AKT/mTOR signaling pathway will increase eIF3f expression.

One known was to do that would be via increasing IGF-1 – insulin-like growth factor 1. You can inject IGF-1 and it has even been trialed in autism.

In New Zealand there is an OTC supplement called CGPMax that claims to increase IGF-1.

I checked and indeed there is some evidence that CGPMax may also increase the expression of eIF3f.

“There is some evidence that CGPMax may also increase the expression of eIF3f. In a study of ER-positive breast cancer cells, CGPMax was shown to increase the expression of eIF3f mRNA and protein. This was thought to be due to the inhibition of CDK4/6, which led to the activation of the PI3K/AKT/mTOR signaling pathway.”

AI generated

Since our reader is in New Zealand and wants a supplement rather than a drug, I think CGPMax is a good fit and certainly worth a trial.

One of the substances suggested by the RGD site was valproic acid.  This looked great news because valproic acid, an anti-epileptic drug (AED), is often used to safely treat even young children.

Why does Valproic acid apparently increase eIF3f mRNA?  That would highly likely be down to it being an HDAC inhibitor which causes it to make epigenetic changes that turn on/off our genes.

We know that some single gene autism can be treated by HDAC inhibitors, at least in mouse models. The potent HDAC inhibitors are now used to treat cancer. One parent I met at the Thinking Autism conference was desperate to access one of these potent drugs for her child’s single gene autism, similar to Kabuki syndrome.

Broccoli sprouts produce an HDAC inhibitor, called sulforaphane.

I could not find any supporting data why valproic acid was listed, the linked reference did not actually refer to eIF3f.

Nonetheless it is harmless to try broccoli sprouts.

 

Quercetin

Another common product popped up in my brief review and that was Quercetin. I had not expected to find that. There is a reaction between quercetin and eIF3f. It is not fully understood. 

Quercetin is a widely available OTC product and simple to trial.

 

Estradiol

It is known that estradiol can increase the expression of eIF3f.

The effect of estradiol on eIF3f expression is likely mediated by the estrogen receptor alpha (ERα).  We have seen that estrogen receptor beta (ERβ) is under-expressed in autism.

Increasing estradiol, or indeed reducing testosterone, has been proposed as an autism therapy. This is not a simple strategy.  In cancer therapy radical steps are taken to reduce sex hormones, because it is the only way to stop the growth of certain types of cancer.

Disturbing the level of male/female hormones will have body-wide effects.  The “men” who currently take large doses of female hormones are going to have consequences later in life.

There is dietary therapy in the form of phytoestrogens that is known to be safe.  The Japanese eat a lot of soy products.

Soy is a particularly good source of phytoestrogens, especially a type of phytoestrogen called isoflavones. Isoflavones are similar in structure to estrogen, but they are much weaker.

Incorporating more soy products into diet would seem a reasonable strategy.

 

Others

There is some evidence that the antibiotic gentamicin can activate the gene eIF3f.  It is given by injection.

Among the list of substance that can increase eIF3f mRNA are some quite toxic substances like BPA found in plastic packaging.  Another interesting option was listed under “anti-rheumatic drugs”, this actually refers to tocilizumab. This is an anti-arthritis drug given to people over the age of two.  Since it ends in -mab, we can infer that it contains monoclonal antibodies, in this case to interleukin-6.

Tocilizumab would likely be helpful in many people with other kinds of autism with a strong auto-immune component.

 

eIF3f-specific treatments vs treat as idiopathic autism

We know from readers with children with different single gene autisms, that are supposed to be untreatable, that these children often respond well to therapies in use for autism of unknown origin (idiopathic autism).

Almost all autism features neuroinflammation, activated microglia etc. Most autism features oxidative stress.  Most autism features impaired myelination. Much autism features mitochondrial dysfunction.

There are specific insights that a genetic diagnosis does give you.  In the case of eIF3f, we are dealing with hypo-active (REDUCED) pro-growth signaling. That means the opposite to the kids born with macrocephaly (big heads).

 


This excellent framework was explained in this old post

https://www.epiphanyasd.com/2015/12/one-of-thousands-autism.html

IGF-1 was mentioned earlier as a possible therapy.  Note that growth hormone (GH) is made in the anterior pituitary gland, it is released into the blood stream, and then stimulates the liver to produce IGF-1. IGF-1 then stimulates systemic body growth, and has growth-promoting effects on almost every cell in the body.

More IGF-1 would lead to more growth. Even in an adult you can increase the density of dendritic spines.

As shown in the chart above on the lower right, in today’s disorder we have decreased protein synthesis.

Now back to the science and the basics of this syndrome. 

eIF3f-related neurodevelopmental disorder (EIF3F-RND) is a rare genetic disorder that causes a variety of neurological and developmental problems. It is caused by mutations in the eIF3f gene, which provides instructions for making a protein that is involved in protein synthesis. It has to be inherited from both parents.

If both parents are carriers, there is a 25% chance that each child will have EIF3F-RND, a 50% chance that each child will be a carrier, and a 25% chance that each child will not have EIF3F-RND and will not be a carrier.

If only one parent is a carrier of the mutated gene, there is a 50% chance that each child will be a carrier, and a 50% chance that each child will not be a carrier and will not have EIF3F-RND.

The incidence of EIF3F-related neurodevelopmental disorder (EIF3F-RND) is unknown. However, it is estimated to be a very rare disorder, affecting less than 1 in 100,000 people. This is likely due to the fact that EIF3F-RND is caused by mutations in a single gene. In order for a child to be affected, both parents must carry a copy of the mutated gene. If only one parent is a carrier, the child will be a carrier, but will not be affected.

The incidence of EIF3F-RND may also be underestimated, as it is a relatively newly identified disorder. As more people are diagnosed with the disorder, the incidence rate may increase. 

EIF3F-RND is caused by under-expression of the eIF3f protein.

Symptoms of EIF3F-RND can vary widely from person to person, but may include:

  • Intellectual disability
  • Developmental delay
  • Seizures
  • Hypotonia (low muscle tone)
  • Microcephaly (small head size)
  • Autism spectrum disorder
  • Facial dysmorphism

 

 



Source: https://ojrd.biomedcentral.com/articles/10.1186/s13023-021-01744-1/figures/2

 

Interactions with other genes/proteins 

One feature of the GeneCards website is that you can see a representation of which are the most important interactions of a gene/protein.

This can sometimes suggest a possible therapy, since one of these related genes might be easier to treat.

In the case of eIF3f almost all the interactions are with other elF-somethings.

The RPS-somethings below are all genes that translate mRNA into proteins.

So, everything below is part of the machinery cells have to make proteins.

 

 


 

EIF3F-related neurodevelopmental disorder research

The EIF3F-NDR research is still in its infancy.

There need to be a models made that can suggest which downstream genes are affected and hence might be treatable.

An eIF3f activator is a drug or other compound that can increase the expression or activity of the eIF3f protein.

Currently, there are no known eIF3f activators that are approved for clinical use. However, researchers are developing a number of different approaches to activating EIF3F, including:

  • Small molecule drugs: Researchers are screening libraries of small molecules to identify compounds that can bind to eIF3f and increase its activity.
  • Gene therapy: Gene therapy could be used to deliver a working copy of the eIF3f gene to cells in the nervous system.
  • CRISPR gene editing: CRISPR gene editing could be used to correct mutations in the eIF3f gene.

In addition to the above approaches, there are a number of other things that could potentially be done to activate eIF3f, such as:

  • Identifying and targeting upstream regulators of eIF3f: Researchers could identify and target other proteins or genes that regulate the expression or activity of eIF3f. This could lead to the development of new drugs or other therapies that could be used to activate eIF3f indirectly.
  • Understanding the role of eIF3f in different cell types: Researchers are still learning about the role of eIF3f in different cell types in the nervous system. This knowledge could be used to develop targeted therapies that activate eIF3f in the specific cell types where it is needed most.

  

EIF3F-related neurodevelopmental disorder: refining the phenotypic and expanding the molecular spectrum

 

Background

An identical homozygous missense variant in EIF3F, identified through a large-scale genome-wide sequencing approach, was reported as causative in nine individuals with a neurodevelopmental disorder, characterized by variable intellectual disability, epilepsy, behavioral problems and sensorineural hearing-loss. To refine the phenotypic and molecular spectrum of EIF3F-related neurodevelopmental disorder, we examined independent patients.

Results

21 patients were homozygous and one compound heterozygous for c.694T>G/p.(Phe232Val) in EIF3F. Haplotype analyses in 15 families suggested that c.694T>G/p.(Phe232Val) was a founder variant. All affected individuals had developmental delays including delayed speech development. About half of the affected individuals had behavioral problems, altered muscular tone, hearing loss, and short stature. Moreover, this study suggests that microcephaly, reduced sensitivity to pain, cleft lip/palate, gastrointestinal symptoms and ophthalmological symptoms are part of the phenotypic spectrum. Minor dysmorphic features were observed, although neither the individuals’ facial nor general appearance were obviously distinctive. Symptoms in the compound heterozygous individual with an additional truncating variant were at the severe end of the spectrum in regard to motor milestones, speech delay, organic problems and pre- and postnatal growth of body and head, suggesting some genotype–phenotype correlation.

Conclusions

Our study refines the phenotypic and expands the molecular spectrum of EIF3F-related syndromic neurodevelopmental disorder.

 

The cancer research

Cancer research is much more advanced and better funded than autism research.

As you can see in the table below, decreased expression of eIF3f is feature of several common cancers. If you can upregulate eIF3f you might have a viable cancer therapy.

As in many types of autism, the potential exists to repurpose cancer drugs as and when they get developed and approved. HDAC inhibition is perhaps the best example. So far people are too scared to try the new potent HDAC inhibitors in human single-gene (monogenic) autism.

  

https://theses.hal.science/tel-01679873/document



 


Alternatively, an indirect regulation of the activity of eIF3 is performed by association of its subunits with other proteins involved in the regulation of protein synthesis. For example, the subunit eIF3e binds p56 in interferon-treated or virus-infected mammalian cells, and inhibits the translation in vitro and in vivo [43, 44]. The subunit eIF3g interacts with Paip1, a Poly (A)-binding protein and stimulates translation initiation [45] whereas the subunits eIF3h and eIF3f interact with TRC8, a ubiquitin E3 ligase, and inhibit protein synthesis, possibly through ubiquitilation of eIF3 or some other translational components [46]. These mechanisms and interacting partners render eIF3 a pivotal player in controlling the protein synthesis and degradation. 

All these data confirm that eIF3f has a multileveled control of multiple functions in the cells, outside its usual function in translation. Keeping it in mind, targeting eIF3f may be a strategy to reorganize different intracellular pathways and alter the basis of the balance between cell proliferation and apoptosis. Thus, eIF3f represents a lead candidate to use for biotherapeutic applications both for inhibiting the growth of cancer cells or muscle atrophy and thus preventing its progression into irreversible cachexia.

 

Conclusion

Personally, I would treat EIF3F-NDR with two parallel approaches:

·        As idiopathic autism with hypo-active pro-growth sigaling autism (small heads/microcephaly)

·        Gene specific with clever ideas targeting the effects of eIF3f under-expression.

Is the cognitive impairment responding to bumetanide?  In the models of Rett syndrome and Fragile-X this is the case. For EIF3F-NDR you could just make your own trial.

For sure there will be oxidative stress in EIF3F-NDR due to the malfunctioning in the protein synthesis “machinery”.  NAC is the antioxidant of choice and is OTC.

EIF3F-NDR can be associated with GI dysfunction, as is much of broader autism.  When treated this often leads to improvements in behavior.

Increasing IGF-1 looks achievable.

Nerve growth factor (NGF) may be upregulated by Lion’s Mane mushrooms, according to the research.

BDNF (brain derived neurotropic factor) can be up regulated. Certain foods and nutrients have been shown to increase BDNF levels. For example, one study found that lutein supplementation increased BDNF levels in the blood. Other foods and nutrients that have been shown to increase BDNF levels include omega-3 fatty acids, magnesium, and zinc.  Some drugs increase BDNF such as lithium, SSRIs, modafinil. Statins such as Simvastatin and Atorvastatin are known to increase BDNF.